Last reviewed · How we verify
NCT05860959
SUBLOCADE Long-term Outcomes
trial in Opioid Use Disorder in 480 participants. Completed in 31 August 2025.
31 August 2025
Quick facts
| Lead sponsor | Indivior Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 480 |
| Start date | 31 August 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 49 locations across Sweden, Canada, United States, Australia |
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
Indivior Inc. — full company profile →
Who can join
18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05860959
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other Indivior Inc. trials
Trials by the same sponsor.
- NCT06576843 — INDV-6001 Multiple-Dose Pharmacokinetic Study · Phase 2 · completed
- NCT06384157 — Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder · Phase 2 · completed
- NCT05878210 — Evaluating the SUBLOCADE Treatment Exit Strategy · completed
- NCT05974046 — Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants · Phase 1 · completed
- NCT05694533 — Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05860959 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indivior Inc.
- Last refreshed: 16 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05860959.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing